ReviewFrontiers in allergy2026
The FOXA transcription factors in allergic airway disease and asthma.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Forkhead box A (FOXA) transcription factors are pioneer factors that orchestrate diverse cellular and developmental processes. Within the respiratory system, FOXA1, FOXA2, and FOXA3 have emerged as modulators of pulmonary inflammation, with important implications for the pathogenesis of allergic asthma. In healthy lung and airways, FOXA1 and FOXA2 maintain epithelial integrity and promote ciliated cell development, thereby preserving homeostasis. FOXA2 additionally suppresses Th2 differentiation and goblet cell metaplasia and mucus overproduction. During allergic airway inflammation, FOXA2 expression is decreased and FOXA3 expression is induced by Th2 cytokines. Dysregulation of the FOXA regulatory network disrupts epithelial cell homeostasis and amplifies allergic inflammation, contributing to airway remodelling. Here we will review the potential mechanisms through which the FOXA family modulates airway inflammation, while also addressing gaps in current understanding, such as the context specific regulation of FOXA isoforms, their interplay with cytokine signalling pathways, and the translational relevance of these findings to therapeutic strategies in asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.